TrialUpamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Trial details
- Registry ID
- NCT04723537
- Phase
- Phase 2, Phase 3
Drug research
Part B: Upamostat 200 or 400 mg
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537 | RedHill Biopharma Limited | Phase 2, Phase 3 | Terminated | 2021-12-28Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |